Starling Oncology, Inc. (STLN)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 1
Do Nothing: qualitativeScore 2 is below the required floor of 3 (shadow flag false, so no SHADOW paper admission) and a 9.70% maximum overnight gap (2026-11-09 regular open 3.96 vs 2026-11-06 regular close 3.61) exceeds the 5% ceiling; the chart is also broken (price 4.485 under SMA20 6.36 / SMA50 6.40 / SMA200 4.77 with MACD -0.32), and neither entry type qualifies — a pullback/oversold limit is countertrend (price < SMA50 with macdLine < 0) while a breakout stop above 4.53 yields R/R 0.95 (< 1.0).
Company overview
Starling Oncology, Inc. is a value-based oncology company focused on advancing cancer care in community settings. Founded in 2007, it provides evidence-based cancer treatments, including clinical trials and transfusions, through an integrated platform serving patients, providers, and health plans.
Fundamental
fairStarling Oncology shows improving revenue and cash flow but remains financially fragile with negative equity and high uncertainty.
Starling Oncology is a growth-stage, value-based oncology platform at an operating inflection: revenue is compounding above 25%, gross profit rose 62% in the latest quarter, and both Adjusted EBITDA and operating cash flow have just turned positive, while GAAP losses, negative stockholders' equity, sub-1.0 interest coverage and a grey-zone solvency score keep the risk profile elevated. The 2027 convertible-note maturity was refinanced away in July 2026, but the replacement term loan carries a ~9.7% coupon and a $700M revenue covenant from December 2027, and the cash turn is heavily working-capital assisted. Shares are optically cheap on sales yet expensive on earnings, Adjusted EBITDA and free cash flow, and dilution potential is large. Net: improving fundamentals inside a still-fragile balance sheet - mixed, high-uncertainty.
Sentiment
weakNo actionable catalysts or strong sentiment drivers are present, with media and retail interest low.
The dominant near-term item is the announced Q3 2026 print (2026-11-05), which the tape read as a wash — revenue up 24% to $169.8M with positive adjusted EBITDA against an ~8c EPS miss and FY26 revenue guidance narrowed below consensus — so there is no rewarded bullish catalyst leg, and the follow-on sell-side price-target moves were mixed (BTIG raised to $10, Lake Street and B. Riley cut). The sentiment delta is determinate but mildly negative (baseline polarity_score +0.16 → scoring -0.02), retail is indeterminate on a single zero-comment automated thread, the Red-Flag Screen is clean with no severe or moderate flags, and with only neutral trailing catalysts and an empty forward calendar the setup is absent-to-weak.
Technical
very weakThe technical setup is weak, with the stock trading below key moving averages and negative momentum indicators.
Chart score 1 — broken structure in a reflex bounce. STLN gapped -40.3% on 2026-11-06 (open 6.06 → close 3.62 on 23.9M shares, the session after the 2026-11-05 Q3 report) and the 2026-11-09 session only reclaimed part of it (+23.5% to 4.485) without reclaiming a single moving average: price 4.485 sits below SMA20 6.36, SMA50 6.40, SMA200 4.77, EMA9 5.70 and EMA21 6.15, and is above only the 11-09 daily VWAP 4.17. MACD is -0.32/-0.07/-0.25 (line below signal, both below zero, histogram widening negative) and ADX 24.31 is rising into the decline; RSI 35.42 (up from 25.33) and Williams %R -69.24 mark only the oversold bounce. This is not a base to buy. Independent of the chart, the run is hard-blocked by the qualitative floor (qualitativeScore 2 < 3, shadow flag false, so no paper admission) and by a 9.70% maximum overnight gap against the 5% ceiling.
You’re looking at 2026-11-09 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

